Theravance Biopharma (NASDAQ:TBPH) Stock Passes Above Fifty Day Moving Average – Should You Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.30 and traded as high as $9.44. Theravance Biopharma shares last traded at $9.35, with a volume of 167,372 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Stock Up 2.8 %

The company has a market cap of $468.49 million, a P/E ratio of -9.38 and a beta of 0.15. The business’s 50 day moving average is $9.30 and its 200 day moving average is $9.03.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. As a group, equities research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Activity

In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio purchased a new stake in shares of Theravance Biopharma during the fourth quarter valued at $353,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Theravance Biopharma by 27.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company’s stock valued at $1,412,000 after purchasing an additional 32,534 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Theravance Biopharma in the fourth quarter valued at $119,000. Nuveen Asset Management LLC boosted its holdings in Theravance Biopharma by 10.9% in the fourth quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock valued at $4,665,000 after purchasing an additional 48,635 shares during the last quarter. Finally, Newtyn Management LLC boosted its holdings in Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock valued at $44,767,000 after purchasing an additional 258,337 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.